Jubilant Life Science Ltd has got the final approval for its generic version of non-steroidal anti-inflammatory drug, Indocin from the US health regulator.

The company has said in a BSE filing that the approval for Indomethacin capsules, generic equivalent of Indocin of Iroko, is for multiple strengths of 25 mg and 50 mg.

Indomethacin capsules are used to in treating moderate to severe inflammation and reduce pain.

It further said that “This is the seventh approval that we have received from the USFDA during the current financial year.”

Read EquityPandit’s Technical Analysis on Nifty Pharma